Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion

CNBC — Apr 20, 13:02 PM

Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.

Read full article at CNBC →

Eli Lilly Buys Kelonia

Eli Lilly to buy Boston biotech Kelonia for $3.25 billion Boston Globe — Apr 20, 17:08 PM
Eli Lilly agrees to buy cancer biotech Kelonia for up to $7 billion Boston Globe — Apr 20, 13:46 PM
Eli Lilly Announces $7 Billion Deal. What It Means for the Stock. Barrons — Apr 20, 11:41 AM
Eli Lilly Stock Falls as It Closes in on a $2 Billion Deal. Here’s Why. Barrons — Apr 20, 11:41 AM